Home/Filings/4/0000950170-24-098799
4//SEC Filing

SINGLETON J MATTHEW 4

Accession 0000950170-24-098799

CIK 0001607678other

Filed

Aug 18, 8:00 PM ET

Accepted

Aug 19, 8:11 PM ET

Size

18.5 KB

Accession

0000950170-24-098799

Insider Transaction Report

Form 4
Period: 2024-08-19
Transactions
  • Sale

    Common Stock, par value $0.00001 per share

    2024-08-19$60.01/sh2,500$150,03523,000 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-08-19$61.86/sh4,509$278,93115,444 total
  • Exercise/Conversion

    Common Stock, par value $0.00001 per share

    2024-08-19$3.33/sh+16,000$53,28025,500 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-08-19$61.13/sh3,047$186,24819,953 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-08-19$63.15/sh2,055$129,77513,389 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-08-19$64.10/sh2,388$153,08011,001 total
  • Sale

    Common Stock, par value $0.00001 per share

    2024-08-19$64.88/sh1,501$97,3859,500 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-08-1916,0000 total
    Exercise: $3.33From: 2017-01-04Exp: 2026-01-04Common Stock (16,000 underlying)
Footnotes (7)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.3605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5411 to $61.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.5874 to $62.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.635 to $63.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.64 to $64.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.79 to $64.9056, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Documents

1 file

Issuer

Viking Therapeutics, Inc.

CIK 0001607678

Entity typeother

Related Parties

1
  • filerCIK 0001243514

Filing Metadata

Form type
4
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 8:11 PM ET
Size
18.5 KB